Compare Enveric Biosciences Inc (ENVB) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Trip.com Group Ltd — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Trip.com Group Ltd trades at $43.61 (market cap $26.95B). The key difference: Trip.com Group Ltd is far larger — about 5065.8× Enveric Biosciences Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | TCOM | |
|---|---|---|
Market Cap | $5.32M | $26.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $78.96 |
52-Week Low | $1.28 | $39.84 |
Enterprise Value | $408.82K | $19.65B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Trip.com Group (TCOM) trades at $42.41, showing minimal daily movement with a slight 0.12% gain. The stock faces technical headwinds with a bearish moving average signal and RSI near overbought levels at 76.49. Fundamentally, TCOM exhibits strong profitability with a 48.65% net income margin and attractive valuation multiples including a P/E of 6.44. Recent Q1 2026 earnings of $0.83 per share missed expectations, while revenue guidance for Q2 2026 suggests slower growth of 3%-8%.
The investment outlook remains mixed. Strong cash flow generation and analyst consensus price target of $56.72 indicate significant upside potential. However, near-term risks include regulatory scrutiny in China, margin pressure from rising costs, and technical bearish signals. The stock's current price near the analyst low target of $42.00 suggests limited downside but requires monitoring of Q2 earnings performance and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
